Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Enhancer of zeste homolog 2 (EZH2) is a candidate oncogenic driver due to its prevalent overexpression and aberrant repression of tumor suppressor genes in diverse cancers. Therefore, blocking EZH2 enzyme activity may present a valid therapeutic strategy for the treatment of cancers with EZH2 overex...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xuejiao, Gao, Tiantao, Wang, Ningyu, Feng, Qiang, You, Xinyu, Ye, Tinghong, Lei, Qian, Zhu, Yongxia, Xiong, Menghua, Xia, Yong, Yang, Fangfang, Shi, Yaojie, Wei, Yuquan, Zhang, Lidan, Yu, Luoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751454/
https://www.ncbi.nlm.nih.gov/pubmed/26868841
http://dx.doi.org/10.1038/srep20864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751454/
https://www.ncbi.nlm.nih.gov/pubmed/26868841
http://dx.doi.org/10.1038/srep20864

Ejemplares similares